Search

News Can Co-administration of Dabigatran with Antiretroviral Drugs Be Effective and Safe?

In 2019, the first results regarding the concurrent use of antiretroviral drugs and oral anticoagulants were published. This involved 14 patients with atrial fibrillation and HIV infection, in whom the concurrent administration of dabigatran with antiretroviral drugs was not associated with the occurrence of thromboembolic events or bleeding during follow-up lasting up to 40 months.

Source: Anticoagulant Treatment 6. 5. 2021

News Patient with a History of DOAC Usage in Neurological ICU with Stroke –⁠ Case Study

How should we approach patients with a stroke who are taking direct oral anticoagulants (DOACs) and correctly assess the situation? When should we administer the available antidote according to guidelines? The following case study from the Regional Hospital Liberec illustrates this increasingly common situation.

Source: Anticoagulant Treatment 1. 2. 2023

News Current View on Prophylactic Negative Pressure Wound Therapy in Practice from Surgeons' Perspective

The journal Updates in Surgery recently published the results of a survey on prophylactic negative-pressure wound therapy (pNPWT) conducted among Swiss surgeons. The survey results show how often this therapy is used, in what situations it is typically applied, and what could make negative-pressure wound therapy more attractive in the future.

Source: Wound Healing 17. 6. 2022

News Administration of Fibrinogen Concentrate in Patients with Persistent Bleeding After Cardiac Surgery

Is the administration of fibrinogen concentrate in patients with persistent bleeding after initial cardiac surgery associated with an increased risk of thromboembolic events or death? Authors of a Swedish observational study published last year aimed to answer this question.

Source: Life-threatening Bleeding 20. 5. 2022

News Impact of Combined Oral Contraceptives on Body Weight

A relatively recent study investigated changes in the average body weight of women who used combined oral contraceptives with 30 μg ethinylestradiol (EE) and 3 mg drospirenone (DRSP) or 30 μg EE and 2 mg chlormadinone acetate (CMA) for 6 months, comparing the results between the two groups.

Source: Oral Contraception 10. 4. 2022

News Teriflunomide under the microscope in studies and practice

Not always do the conclusions from clinical studies fully confirm in real clinical practice. Does this also apply to teriflunomide? Is its efficacy and safety consistent across age groups and individual studies?

Source: Multiple Sclerosis 3. 5. 2022

News Venous Insufficiency of the Lower Extremities –⁠ A Diverse Range of Risks, Manifestations, and Complications

Although initially often asymptomatic, chronic venous insufficiency includes a variety of symptoms. Some of its manifestations can be irreversible, increasing the socio-economic burden that this disease, especially in its advanced stages, represents. German authors have summarized the latest findings on the epidemiology, risks, pathogenesis, manifestations, and complications of CVI in their review.

Source: Venous Insufficiency 20. 11. 2020

Články časopisu Chronic lymphocytic leukaemia –⁠ contemporary application of modern prognostic and predictive markers in diagnostics

Author of the article: Š. Pospíšilová, M. Jarošová, M. Doubek Source: Transfuze a hematologie dnes | 1/2019 29. 3. 2019

News How do patients perceive the change in appearance of chronically used medications and to what extent does it lead to non-adherence to therapy?

Doctors regularly encounter patients in their offices who complain about changes in the appearance of their chronically used medications. Such a change can even be the cause of non-adherence to treatment. Interesting findings on this topic were brought by an American survey aimed at identifying the preferences, experiences, and reactions of patients and pharmacists related to changes in the appearance of medications.

Source: Cardiovascular Continuum 23. 2. 2022

News If Suicides Were COVID-19... or Why We Still Overlook a Significant Cause of Premature Deaths?

More than a year since the start of the pandemic, the SARS-CoV-2 coronavirus has claimed 2.8 million lives globally, with 127 million recorded cases of COVID-19 (as of March 29, 2021). According to World Health Organization (WHO) data, there are 800,000 suicides annually, with suicide attempts being up to 20 times more frequent, totaling over 16 million. Given our current focus on physical health, are we overlooking the extent and importance of mental health issues in the population? This question has been raised by several experts from different countries in their submission to the February issue of The Journal of Clinical Psychiatry.

Source: Depression and Anxiety 30. 3. 2021

News Efficacy and Safety of Empagliflozin in Patients with Heart Failure with Preserved Ejection Fraction

Previous studies have shown that the antidiabetic drug empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure with reduced left ventricular ejection fraction (HFrEF), both in diabetics and non-diabetics. The aim of the EMPEROR-Preserved clinical trial was to supplement data on the efficacy and safety of empagliflozin in a population of patients with heart failure with preserved ejection fraction (HFpEF; EF LK > 40%).

Source: Heart Failure 27. 4. 2022

News Efficacy and Safety of the Combination of Telmisartan and Amlodipine with Hydrochlorothiazide in the Treatment of Hypertension

The aim of the study by Korean authors was to evaluate the efficacy and tolerability of the triple combination of telmisartan/amlodipine + hydrochlorothiazide (TAH) compared to the combination of telmisartan/amlodipine (TA) alone in patients with essential hypertension who did not respond sufficiently to a 4-week treatment with TA.

Source: Sartans in the Treatment of Hypertension 8. 2. 2022

News Specific treatment of pulmonary involvement in patients with AAT deficiency −⁠ why, how, and for whom?

For patients with emphysema and decreased lung function due to alpha-1-antitrypsin deficiency (AATD), there is an approved specific treatment which involves the i.v. administration of alpha-1-antitrypsin (AAT) derived from human plasma. This augmentation therapy slows the loss of lung tissue density. Its effects and impact on the frequency and duration of exacerbations, quality of life, lung functions, and patient mortality are less clear.

Source: Deficiency of Alpha-1-Antitrypsin 1. 11. 2022

News Long-term Safety and Efficacy of Ozanimod in the Treatment of Relapsing Forms of MS

Ozanimod is classified as a modulator of sphingosine-1-phosphate (S1P) receptors types 1 and 5. It is approved for the treatment of relapsing-remitting multiple sclerosis (RRMS) and moderate to severe ulcerative colitis (UC) and continues to undergo intensive clinical research. The DAYBREAK open-label, single-arm study for participants with RRMS from previous trials with ozanimod was scheduled to be completed by January 2023, and its final results can therefore be expected soon. The following article presents the interim analysis results of this study 5 years after initiation.

Source: Modulation of S1P in the Treatment of Autoimmune Diseases 28. 8. 2023

News Impact of Dabigatran and Warfarin Treatment on the Risk of Acute Kidney Injury in Patients with Atrial Fibrillation

What clinical characteristics in patients with non-valvular atrial fibrillation may indicate a higher risk of acute kidney injury? Does the modality of anticoagulation therapy play a role in its incidence? These questions were the focus of an extensive retrospective study conducted in an Asian setting.

Source: Anticoagulant Treatment 23. 4. 2020